They subsequently discovered that HER2-targeting CAR-M cells not only exhibited a specific killing ability in vitro and in vivo, but also induced a pro-inflammatory TME and boosted anti-tumor T cell activity by producing pro-inflammatory cytokines and chemokines, converting bystander M2 macrophages into M1, and upregulating antigen-presenting machinery [369]. Here, ERBB2 is linked to neoplasm.